Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26469358 | 0.85 | LMNA (0.69) | LMNATSHR | |
| SCHEMBL8739738 | 0.75 | — | — | |
| SCHEMBL19718306 | 0.74 | TSHR (0.62) | LMNATSHR | |
| SCHEMBL9889751 | 0.72 | LMNA (0.48) | LMNATSHR | |
| SCHEMBL26210094 | 0.71 | LMNA (0.46) | LMNATSHR | |
| SCHEMBL26210832 | 0.69 | LMNA (0.45) | LMNATSHR | |
| SCHEMBL20630575 | 0.69 | TSHR (0.48) | LMNATSHR | |
| SCHEMBL26010515 | 0.69 | LMNA (0.46) | LMNATSHR | |
| SCHEMBL13083513 | 0.68 | PRMT3 (0.35) | LMNA | |
| SCHEMBL26208784 | 0.68 | LMNA (0.43) | LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9498518-B2 | Targeting of glycoprotein therapeutics | GENZYME CORPORATION (US) | 2016-11-22 | — | — | US | disclosed |
| US-20150320844-A1 | TARGETING OF GLYCOPROTEIN THERAPEUTICS | GENZYME CORPORATION (US) | 2015-11-12 | — | — | US | disclosed |
| US-7341720-B2 | Improved targeting of glycoproteins to specific tissues is achieved by masking the natural carbohydrate and other surface determinants with high molecular weight polymers, such as, e.g., PEG, polysialic acid, etc.; treatment of lysosomal storage disorders | GENZYME CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150320844-A1 | TARGETING OF GLYCOPROTEIN THERAPEUTICS | SIGLEC7, LAMP2, ASGR1 | LMNA 2289/4885TSHR 1391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.